- Home
- PSNL vs CGEM Comparison
PSNL vs CGEM Comparison
Compare PSNL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- CGEM
- Stock Information
- Founded
- PSNL 2011
- CGEM 2016
- Country
- PSNL United States
- CGEM United States
- Employees
- PSNL N/A
- CGEM N/A
- Industry
- PSNL Medical Specialities
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- CGEM Health Care
- Exchange
- PSNL Nasdaq
- CGEM Nasdaq
- Market Cap
- PSNL 484.0M
- CGEM 482.7M
- IPO Year
- PSNL 2019
- CGEM 2021
- Fundamental
- Price
- PSNL $5.24
- CGEM $6.99
- Analyst Decision
- PSNL Strong Buy
- CGEM Strong Buy
- Analyst Count
- PSNL 4
- CGEM 7
- Target Price
- PSNL $8.13
- CGEM $26.57
- AVG Volume (30 Days)
- PSNL 900.5K
- CGEM 456.2K
- Earning Date
- PSNL 11-05-2025
- CGEM 11-06-2025
- Dividend Yield
- PSNL N/A
- CGEM N/A
- EPS Growth
- PSNL N/A
- CGEM N/A
- EPS
- PSNL N/A
- CGEM N/A
- Revenue
- PSNL $80,317,000.00
- CGEM N/A
- Revenue This Year
- PSNL N/A
- CGEM N/A
- Revenue Next Year
- PSNL $29.83
- CGEM N/A
- P/E Ratio
- PSNL N/A
- CGEM N/A
- Revenue Growth
- PSNL 0.36
- CGEM N/A
- 52 Week Low
- PSNL $2.83
- CGEM $6.61
- 52 Week High
- PSNL $7.79
- CGEM $19.66
- Technical
- Relative Strength Index (RSI)
- PSNL 54.55
- CGEM 40.83
- Support Level
- PSNL $4.73
- CGEM $6.61
- Resistance Level
- PSNL $4.97
- CGEM $7.82
- Average True Range (ATR)
- PSNL 0.26
- CGEM 0.45
- MACD
- PSNL 0.10
- CGEM -0.06
- Stochastic Oscillator
- PSNL 96.39
- CGEM 22.22
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.